Radiolabeled Monoclonal Antibody Imaging Of Tumors And P

肿瘤和肿瘤的放射性标记单克隆抗体成像

• 批准号: 6675158
• 负责人: JORGE A. CARRASQUILLO
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6675158
• 关键词: Animalia; antitumor antibody; blood flow measurement; clinical trials; diagnosis design /evaluation; human subject; human therapy evaluation; immunologic substance development /preparation; monoclonal antibody; neoplasm /cancer immunodiagnosis; neoplasm /cancer radioimmunotherapy; neoplasm /cancer radionuclide diagnosis; nonhuman therapy evaluation; nuclear medicine; patient oriented research; pharmacokinetics; positron emission tomography; radiation therapy dosage; radionuclide imaging /scanning; radionuclides; radiopharmacology

These studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (PI), in which we used humanized anti-tac monoclonal antibody, is ongoing. A collaborative radioimmunotherapy trial with bone marrow support is ongoing with NCI(Dr, Bishop and Pastan). Various protocols using [F-18] FDG in PET and [O-15] water for tumor detection, followup, and blood flow measurements are ongoing with NCI surgery Branch (Dr. Libutti). There are 4 ongoing collaborative studies evaluating fluorodeoxyglucose-PET for assessing tumor response to treatment (Dr. Swain, Dr. Mackall, Dr. Sausville and Dr. Wilson). We have evaluated the use of fluorodeoxyglucose-PET in assesing sites of viral replication in patients with HIV (Dr. Brust). We have utilized FDG-PET to evaluate sites of metabolic activity in patients with systemic lupus erythematosus. We have perfomed preclinical studies evaluating pretargeting of antibodies for tumor therapy and have demonstrated therapeutic responses with Y-90 and Bi-213 in animal tumor models. Two antibody -strepavidin conjugates have been evaluated preclinically and paper have been accepted for publication. We are evaluating a third anti-mesothelin-strepavidin conjugated antibody.

这些研究旨在开发检测和治疗恶性肿瘤的改进方法。我们的团队在国立癌症研究所的各个实验室进行初步筛选后，对似乎有希望的抗体进行临床前评估，并开发这些抗体用于临床应用。本课题组进行了药代动力学和剂量学的临床试验。与Waldmann博士（PI）合作的放射免疫治疗试验正在进行中，我们使用了人源化抗tac单克隆抗体。NCI（Bishop和Pastan博士）正在进行一项骨髓支持的放射免疫治疗合作试验。NCI外科分支正在进行各种方案，使用PET中的[F-18] FDG和[O-15]水进行肿瘤检测、随访和血流测量（Libutti博士）。有4项正在进行的合作研究评价氟脱氧葡萄糖-PET用于评估肿瘤对治疗的反应（Swain博士、Mackall博士、Sausville博士和Wilson博士）。我们评估了氟脱氧葡萄糖PET在评估HIV患者病毒复制位点中的应用（Dr. Brust）。我们利用FDG-PET来评估系统性红斑狼疮患者的代谢活动部位。我们已经进行了临床前研究，评估用于肿瘤治疗的抗体的预靶向，并在动物肿瘤模型中证明了Y-90和Bi-213的治疗反应。两种抗体-链霉亲和素偶联物已进行临床前评价，论文已被接受发表。我们正在评估第三种抗间皮素-链霉亲和素缀合抗体。